BOLT Stock Summary and Trading Ideas (Bolt Biotherapeutics | NASDAQ:BOLT)

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Bolt Biotherapeutics trades on the NASDAQ stock market under the symbol BOLT.

As of December 19, 2025, BOLT stock price climbed to $5.16 with 19,356 million shares trading.

BOLT has a beta of 0.59, meaning it tends to be less sensitive to market movements. BOLT has a correlation of 0.03 to the broad based SPY ETF.

BOLT has a market cap of $9.90 million. This is considered a Sub-Micro Cap stock.

Last quarter Bolt Biotherapeutics reported $2 million in Revenue and -$3.72 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $1.54.

In the last 3 years, BOLT traded as high as $40.60 and as low as $4.41.

The top ETF exchange traded funds that BOLT belongs to (by Net Assets): VXF.

BOLT has underperformed the market in the last year with a price return of -48.8% while the SPY ETF gained +18.1%. BOLT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -1.3% and -4.8%, respectively, while the SPY returned +2.8% and -0.5%, respectively.

BOLT support price is $4.85 and resistance is $5.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BOLT shares will trade within this expected range on the day.